TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 53.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 150,907 shares of the company's stock after selling 172,443 shares during the quarter. Emerald Advisers LLC owned about 0.45% of TransMedics Group worth $23,692,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TMDX. BNP Paribas Financial Markets increased its holdings in shares of TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock valued at $1,286,000 after purchasing an additional 4,518 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group in the first quarter valued at approximately $35,000. RiverPark Advisors LLC increased its stake in TransMedics Group by 361.1% during the first quarter. RiverPark Advisors LLC now owns 6,082 shares of the company's stock worth $450,000 after acquiring an additional 4,763 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in TransMedics Group by 156.6% during the first quarter. Oppenheimer & Co. Inc. now owns 26,570 shares of the company's stock worth $1,965,000 after acquiring an additional 16,214 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company's stock worth $1,997,000 after acquiring an additional 26,997 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Morgan Stanley raised their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an "equal weight" rating in a research note on Monday, July 15th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. Oppenheimer cut their target price on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 29th. JPMorgan Chase & Co. cut their target price on TransMedics Group from $173.00 to $116.00 and set an "overweight" rating for the company in a research note on Tuesday, October 29th. Finally, Stephens raised their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $144.80.

TransMedics Group Stock Up 0.5 %

NASDAQ:TMDX traded up $0.43 during midday trading on Friday, reaching $82.40. The company had a trading volume of 1,818,675 shares, compared to its average volume of 1,961,312. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of 87.66 and a beta of 2.08. The stock's fifty day simple moving average is $140.51 and its 200-day simple moving average is $139.98. TransMedics Group, Inc. has a 12-month low of $38.13 and a 12-month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 8.48 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts' expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.12) earnings per share. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.08 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at $8,180,642.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company's stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 61,247 shares of company stock worth $9,518,181. Company insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.